SSR3 acts as a novel oncogene in hepatocellular carcinoma (HCC) and therefore can serve as a biomarker for the prognosis of HCC patients.[22] However, there are no reports of a relationship between this gene and hematological disorders. This evidence concerns the gene SSR3 and hematologic disorder.